ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2025

Abstract Number: 0652

Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation

Brandon Jackson1, Saira Sheikh2, Roberto Caricchio3, Taylor Irons4, Maria Dall'Era5, Amit Saxena6, Alfred Kim7, Jose Rubio8, Sasha Bernatsky9, David Goddard10, Fotios Koumpouras11, Aimee Williams12, Maya Merrell13, Jennifer Meriwether14 and Stacie Bell15, 1Lupus Therapeutics, Miami, FL, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3University of Massachusetts Chan Medical School, Worcester, MA, 4Lupus Therapeutics, Houston, TX, 5Division of Rheumatology, University of California, San Francisco, CA, 6NYU Grossman School of Medicine, New York, NY, 7Washington University School of Medicine, St. Louis, MO, 8University of Alabama at Birmingham, Hoover, AL, 9Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 10NYU Langone Grossman SOM, Brooklyn, NY, 11Yale School of Medicine, New Haven, CT, 12Lupus Therapeutics, Raleigh, NC, 13Lupus Therapeutics, Charleston, SC, 14Lupus Therapeutics, Westminster, CO, 15Lupus Therapeutics, Lakewood, CO

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2025

Keywords: Education, Health Services Research, Surveys, Systemic lupus erythematosus (SLE)

Session Information

Date: Sunday, October 26, 2025

Title: (0641–0670) Systemic Lupus Erythematosus – Treatment Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Lupus Therapeutics (LT), the clinical affiliate of the Lupus Research Alliance, oversees the premier North American Lupus Clinical Investigators Network (LuCIN). As cell therapy emerges as a potentially transformative, but operationally demanding modality in lupus trials, understanding site readiness and barriers is essential. To address the anticipated expansion of cell therapy trial activity, an annual network-wide survey was conducted to assess the capability and requirements necessary for sites to engage in cell therapy clinical studies.

Methods: Using an internet-based platform, an annual survey was administered between Dec 17, 2024, and Feb13, 2025; a total of 60 LuCIN sites submitted multiple team responses. The survey asked about institutional infrastructure, interdepartmental collaboration, readiness for various cell therapy modalities, and educational/training priorities.

Results: Of the 124 respondents, enthusiasm for cell therapy was high: 60% expressed a preference to participate in Phase 2 trials while 35% in Phase 1 cell therapy trials. Chimeric antigen receptor T-cell (CAR-T) was the preferred modality (75%) followed by allogenic CAR-Natural Killer cell (44%) or other allogeneic approaches (40%) Table 1. Most sites (≥74%) reported the presence of core inpatient infrastructure (e.g., apheresis, drug storage, certified infusion providers, SOPs, toxicity monitoring), 62% had outpatient infusion capabilities, highlighting significant network readiness and evolution to adopt cell therapy for further study in lupus. Interdepartmental collaboration was active, as 66% reported partnerships with oncology/hematology and 59% seeking training to enable further collaboration. The most common operational challenges were logistical hurdles (74%), competing clinical studies (58%), and limited shared staffing capacity (39%). Meanwhile, 48% of respondents noted there are “too many” cell therapy opportunities. Investment in cell therapy capabilities, while increasing, was uneven where 59% reported enhanced multidisciplinary collaboration, 31% on additional staff or expertise and 20% reported new infrastructure, but 31% reported no new investments. Educational gaps were present as 76% requested new patient education materials, including CAR-T, with a priority on safety monitoring (66%), recruitment and patient education (64%), clinical protocol design (61%), among others (Table 2). Respondents identified target audiences of research staff (64%), patients (62%), and providers (56%) for cell therapy education opportunities.

Conclusion: Understanding readiness for cell therapy in lupus is critical to build a network of capable cell-therapy trialists for lupus and beyond. Using this knowledge, strategic investment in operational planning, capacity building and tailored education efforts for staff, patients, and providers will provide the research community support for the safe, effective and scalable integration of cell therapy in lupus trials. Careful attention to resource allocation, multidisciplinary partnerships and trial prioritization will be essential to avoid saturation and sustain momentum across LuCIN sites.

Supporting image 1Table 1: Trial Preferences and Cell Therapy Readiness Across LuCIN Sites

Supporting image 2Table 2: Barriers, Investments, and Educational Needs for Cell Therapy Trials


Disclosures: B. Jackson: None; S. Sheikh: AstraZeneca, 1, Aurinia Pharmaceuticals, 5, Biogen, 1, Cabaletta Bio, 5, GlaxoSmithKlein(GSK), 1; R. Caricchio: Abbvie, 1, Cabaletta, 5, GlaxoSmithKlein(GSK), 1, Kyverna, 5, Novartis, 1; T. Irons: None; M. Dall'Era: AstraZeneca, 2, Aurinia, 2, Biogen, 2, Genentech, Inc., 2, GlaxoSmithKline (GSK), 2, Janssen, 2; A. Saxena: AbbVie/Abbott, 1, Amgen, 1, AstraZeneca, 1, Aurinia, 1, 6, Bristol-Myers Squibb(BMS), 1, GlaxoSmithKlein(GSK), 5, Synthekine, 1, 2, UCB, 1, 6; A. Kim: Abbvie, 2, AstraZeneca, 2, 5, Atara Bio, 2, Bristol Myers Squibb, 5, Cargo Therapeutics, 2, CRISPR Therapeutics, 1, 5, Exagen Diagnostics, 2, 6, Genentech/Roche, 2, GlaxoSmithKline, 2, 6, Hinge Bio, 2, Invivyd, 2, Kypha, Inc., 2, 10, Novartis, 5, Zenas BioPharma, 2; J. Rubio: None; S. Bernatsky: None; D. Goddard: UCB, 5; F. Koumpouras: AbbVie/Abbott, 5, Adicet Bio, 2, AstraZeneca, 1, 2, 5, 6, Atara Bio, 2, Bristol-Myers Squibb(BMS), 5, 12, Clinical Trial, Cabaletta Bio, 2, Gilead, 12, Clinical Trial, GlaxoSmithKlein(GSK), 2, 5, ITN, 12, Clinical Trial, LRA/LuCIN, 5, Miltenyi Bio, 2, NIH, 5, Novartis, 2, RRF, 5, UCB, 12, Clinical Trial; A. Williams: None; M. Merrell: None; J. Meriwether: None; S. Bell: None.

To cite this abstract in AMA style:

Jackson B, Sheikh S, Caricchio R, Irons T, Dall'Era M, Saxena A, Kim A, Rubio J, Bernatsky S, Goddard D, Koumpouras F, Williams A, Merrell M, Meriwether J, Bell S. Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/evolution-and-readiness-preparing-for-cell-therapy-in-lupus-trials-a-lucin-network-evaluation/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evolution-and-readiness-preparing-for-cell-therapy-in-lupus-trials-a-lucin-network-evaluation/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology